Stockholm-headquartered radiotherapy and radiosurgery specialist with long-standing installations in Portuguese hospitals, including linear accelerators and the Leksell Gamma Knife.
Elekta (STO: EKTA-B), founded in Stockholm in 1972 by neurosurgeon Lars Leksell, is one of two global leaders in precision radiotherapy and radiosurgery alongside US-based Varian. Portugal has been an Elekta customer market for decades, with Versa HD and Synergy linear accelerators installed in oncology centres operated by both the public Serviço Nacional de Saúde and private hospital groups.
The company's presence in Portugal stretches from Hospital CUF Infante Santo in Lisbon — which runs an Elekta linear accelerator for external-beam radiotherapy — to IPO Lisboa, IPO Porto and IPO Coimbra, the three national oncology institutes that have historically specified Elekta kit alongside Varian in multi-vendor procurement. The Portuguese footprint also includes Leksell Gamma Knife stereotactic radiosurgery units used for intracranial cancers.
Portugal's oncology investment is accelerating as the country works through EU Recovery and Resilience Plan health-sector funds and the SNS digital transformation programme. Radiotherapy equipment replacement cycles typically run ten to twelve years, and a significant share of the Portuguese installed base is approaching renewal — a structural tailwind for Elekta as it competes with Varian for the next wave of linac tenders. Elekta's Swedish R&D heritage and Nordic clinical reference sites give it a credible story inside Portuguese hospital procurement.
Fractio helps Nordic companies enter the Portuguese market — from market sizing to first sales, hiring, and legal setup.
Talk to Fractio →